Quest Diagnostics Incorporated (DGX) Q2 FY26 Earnings Call

Strong organic growth and raised 2026 guidance coexist with margin, ACA, PAMA, and fuel risks.

Q2 FY26 results, source: company transcript and SEC filings
QuarterQ2 FY26
Length56 minutes
EPS$3.12
EPS consensus$2.81

What changed, guidance prior to now, analyst Q&A candor and the case for and against are part of Core.

Other quarters: Q1 FY26 · Q1 FY25 · Q2 FY24

All DGX earnings · Back to DGX overview

Transcript produced by Signals.AI from the company's own earnings call audio. Not personalized investment advice.